

Ruth L Goodall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7478870/publications.pdf>

Version: 2024-02-01

30
papers

844
citations

567281
15
h-index

477307
29
g-index

32
all docs

32
docs citations

32
times ranked

1479
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2012, 308, 353-61.	7.4	146
2	Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatric Infectious Disease Journal, 2003, 22, 56-62.	2.0	140
3	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Medicine, 2018, 15, e1002514.	8.4	98
4	EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine, 2008, 26, 3153-3161.	3.8	54
5	Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine+Lamivudine plus Nevirapine and Zidovudine+Lamivudine plus Abacavir. Journal of Infectious Diseases, 2010, 201, 106-113.	4.0	46
6	High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy. Clinical Infectious Diseases, 2014, 58, 1023-1026.	5.8	36
7	TIMING AND INTERPRETATION OF TESTS FOR DIAGNOSING PERINATALLY ACQUIRED HEPATITIS C VIRUS INFECTION. Pediatric Infectious Disease Journal, 2001, 20, 715-716.	2.0	32
8	Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study. PLoS Medicine, 2018, 15, e1002491.	8.4	29
9	Interval-censored survival time data: confidence intervals for the non-parametric survivor function. Statistics in Medicine, 2004, 23, 1131-1145.	1.6	27
10	Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1. Antimicrobial Agents and Chemotherapy, 2011, 55, 1806-1809.	3.2	21
11	Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 277-283.	2.1	20
12	Bronchopulmonary Kaposi s sarcoma in 106 HIV 1 infected patients. International Journal of STD and AIDS, 1998, 9, 518-525.	1.1	17
13	A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria. PLoS ONE, 2013, 8, e57580.	2.5	17
14	Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. PLoS ONE, 2015, 10, e0137834.	2.5	17
15	Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. PLoS ONE, 2011, 6, e14764.	2.5	16
16	Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPs): a cohort study. Lancet HIV, 2015, 2, e530-e539.	4.7	16
17	Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. AIDS Research and Human Retroviruses, 2015, 31, 1032-1037.	1.1	15
18	Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa. Journal of Antimicrobial Chemotherapy, 2017, 72, 1450-1455.	3.0	15

#	ARTICLE	IF	CITATIONS
19	Health-Related Quality of Life Outcomes in HIV-Infected Patients Starting Different Combination Regimens in a Randomized Multinational Trial: The INITIO-QoL Substudy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1215-1222.	1.1	14
20	High HIV prevalence and incidence among women in Southern Mozambique: Evidence from the MDP microbicide feasibility study. <i>PLoS ONE</i> , 2017, 12, e0173243.	2.5	13
21	Outcomes after viral load rebound on first-line antiretroviral treatment in children with HIV in the UK and Ireland: an observational cohort study. <i>Lancet HIV</i> , 2015, 2, e151-e158.	4.7	12
22	High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial. <i>PLoS ONE</i> , 2014, 9, e90772.	2.5	9
23	Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 70, 404-415.	5.8	8
24	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. <i>Journal of the International AIDS Society</i> , 2022, 25, e25871.	3.0	8
25	Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25477.	3.0	5
26	The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data. <i>BMC Infectious Diseases</i> , 2017, 17, 160.	2.9	3
27	Lack of Minority K65R-Resistant Viral Populations Detected After Repeated Treatment Interruptions of Tenofovir/Zidovudine and Lamivudine in a Resource-Limited Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 215-216.	2.1	2
28	Inpatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 749-756.	1.1	2
29	Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis. <i>Trials</i> , 2022, 23, .	1.6	2
30	Resistance and Virological Response Analyses in a Three Initial Treatment Strategy Trial: A Substudy of the INITIO Trial. <i>HIV Clinical Trials</i> , 2009, 10, 385-393.	2.0	1